Compare Intercept Pharmaceuticals vs Neuraltus Pharmaceuticals
Customers evaluate the quality of Intercept Pharmaceuticals's products using the following success metrics.
Overview
Intercept Pharmaceuticals is 22 yrs old and is based in United States.
Intercept is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe, and Canada.
Neuraltus Pharmaceuticals is based in United States
Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.
Demo Video
Leadership
Mark Pruzanski (Founder)
Richard L Casey (Chief Executive Officer)
Funding
Investors
Genextra, OrbiMed Advisors
Latterell Venture Partners, VantagePoint Capital Partners
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Intercept Pharmaceuticals has not claimed their profile.
Work for Intercept Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Intercept Pharmaceuticals?
Claim your profile now.
Information not available because Neuraltus Pharmaceuticals has not claimed their profile.
Work for Neuraltus Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Neuraltus Pharmaceuticals?
Claim your profile now.